Page 1 of Clinical Trials for ( Tibotec AND Inc ) [SPONSOR-COLLABORATORS], 14 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.
Last Updated: January 13, 2011
Condition(s): HIV Infections; Infection
2
Active, not recruiting
INROADS, Abbreviated Title: Intelence aNd PRezista Once A Day Study
Last Updated: May 15, 2012
Condition(s): HIV
3
Completed
A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Last Updated: December 30, 2010
Condition(s): HIV Infections
4
Completed
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
Last Updated: November 30, 2011
Condition(s): HIV
5
Completed
A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
Last Updated: October 18, 2010
Condition(s): HIV-1 Infection
6
Active, not recruiting
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
Last Updated: May 4, 2012
Condition(s): HIV
7
Recruiting
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women
Last Updated: May 16, 2012
Condition(s): HIV; HIV Infections; Pregnancy
8
Recruiting
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
Last Updated: July 16, 2010
Condition(s): HIV Infections; Hepatitis B Virus
9
Completed
Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)
Last Updated: August 31, 2009
Condition(s): HIV Infections
10
Completed
Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium
Last Updated: August 31, 2009
Condition(s): HIV Infections
11
Completed
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma HCV RNA Levels Did Not Respond to Therapy
Last Updated: June 22, 2011
Condition(s): Hepatitis C
12
Active, not recruiting
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Last Updated: June 13, 2011
Condition(s): HIV-1 Infection; HIV Infections
13
Recruiting
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
Last Updated: February 12, 2010
Condition(s): HIV Infections
14
Completed
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Last Updated: June 6, 2011
Condition(s): Metastatic Breast Cancer

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?spons=Tibotec%2C+Inc

Page 1 of Clinical Trials for ( Tibotec AND Inc ) [SPONSOR-COLLABORATORS], 14 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About